Skip to main content
NCBI home page
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
. 1993 Mar;119(3):131–136. doi: 10.1007/BF01229526

Effect of anti-CD3/anti-CD28/interleukin-2 stimulation of mononuclear cells on transforming growth factorβ inhibition of lymphokine-activated killer cell generation

Jaroslaw Koberda 1,✉, Elizabeth A Grimm 3, Richard P Moser 1
PMCID: PMC12200769  PMID: 8380285

Abstract

After simultaneous stimulation with anti-CD3 monoclonal antibody (mAb) at 10 ng/ml, anti-CD28 mAb at 125 ng/ml, and interleukin-2 (IL-2) at 20 U/ml, peripheral blood mononuclear cells (PBMC) were partially resistant to immunosuppression by transforming growth factor-β (TGFβ2). The doses of TGFβ2 that inhibit cytotoxicity of IL-2 stimulated cells by 60%–70% were much less effective when the same cells were stimulated with anti-CD3/anti-CD28/IL-2. This favorable stimulation generated a cell population characterized by high lytic activity, excellent expansion, and a greater resistance to immunosuppressive action of TGFβ2. The secretion of secondary cytokines important for LAK generation is considered a crucial event, at least partially responsible for the antagonization of TGFβ immunosuppression.

Key words: CD28 lymphocyte stimulation, TGFβ

Abbreviations

CTL

cytotoxic T lymphocyte

LAK

lymphokine-activated killer cell

mAb

monoclonal antibotly

PBMC

peripheral blood mononuclear cell

NK

matural killer

LU

lytic unit

IL-2

interleukin-2

IL-2R

interleukin-2 receptor

TNF

tumor necrosis factor

TGF

transforming growth factor

IFN

interferon

References

  1. Anderson PM, Bach FH, Ochoa AC (1988) Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Cancer Immunol Immunother 27:82 [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bugis SP, Lotzova E, Savage H, Hester J, Racz T, Sacks PG, Schantz SP (1990) Inhibition of lymphokine-activated killer cell generation by blocking factors in sera of patients with head and neck cancer. Cancer Immunol Immunother 31:176 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Damle NK, Doyle LV (1989) Stimulation via the CD3 and CD28 molecules induces responsiveness to IL-4 in CD4+CD29+CD45R− memory T lymphocytes. J Immunol 143:1761 [PubMed] [Google Scholar]
  4. Espevik T, Figari IS, Ranges GE, Palladino MA (1988) Transforming growth factor-betal (TGF-beta1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. J Immunol 140:2312 [PubMed] [Google Scholar]
  5. Fraser JD, Irving BA, Crabtree GR, Weiss A (1991) Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science 251:313 [DOI] [PubMed] [Google Scholar]
  6. Grimm EA, Crump WL III, Durett A, Hester JP, Lagoo-Deenadalayan S, Owen-Schaub LB (1988) TGFβ inhibits the in vitro induction of lymphokine-activated killing activity. Cancer Immunol Immunother 27:53 [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Grimm EA, Bruner JM, Carinhas J, Koppen JA, Loudon WG, Owen-Schaub L, Steck PA, Moser RP (1991) Characterization of IL-2-initiated versus OKT3-initiated human tumor infiltrating lymphocytes from glioblastoma multiforme: growth characteristics, cytolytic activity, and cell phenotype. Cancer Immunol Immunother 32:391 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Guillou PJ, Sedman PC, Ramsden CW (1989) Inhibition of lymphokine-activated killer cell generatiion by cultured tumor cell lines in vitro. Cancer Immunol Immunother 28:43 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hess AD, Bright EC (1991) The effect of the CD28 activation pathway on the immunosuppressive action of cyclosporine. Transplantation 51:1232 [DOI] [PubMed] [Google Scholar]
  10. Hirte H, Clark DA (1991) Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: identification of transforming growth factor β as a suppressive factor. Cancer Immunol Immunother 32:296 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ikeda T, Lioubin MN, Marquardt H (1987) Human transforming growth factor type beta2: production by a prostatic adenocarcinoma cell line, purification, and initial characterisation. Biochemistry 26:2406 [DOI] [PubMed] [Google Scholar]
  12. Janeway CA Jr (1989) The role of CD4 in T-cell activation: accessory molecule or co-receptor? Immunol Today 10:234 [DOI] [PubMed] [Google Scholar]
  13. June CH, Jackson KM, Ledbetter JA, Leiden JM, Lindsten T, Thompson CB (1989) Two distinct mechanisms of interleukin-2 gene expression in human T lymphocytes. J Autoimmun 2[Suppl]:55 [DOI] [PubMed] [Google Scholar]
  14. June CH, Ledbetter JA, Linsley PS, Thompson CB (1990) Role of the CD28 receptor in T-cell activation. Immunol Today 11:211 [DOI] [PubMed] [Google Scholar]
  15. Kabelitz D (1990) Do CD2 and CD3-TCR T-cell activation pathways function independently. Immunol Today 11:44 [DOI] [PubMed] [Google Scholar]
  16. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn MB, Fauci AS (1986) Production of transforming growth factor-beta by human lymphocytes and its possible role in the regulation of T cell growth. J Exp Med 163:1037 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kehrl JH, Taylor AS, Delsing GA, Roberts AB, Sporn MB, Fauci AS (1989) Further studies of the role of transforming growth factor-beta in human B cell function. J Immunol 143:1868 [PubMed] [Google Scholar]
  18. Kuppner MC, Hamou MF, Bodmer S, Fontana A, De Tribolet N (1988) The glioblastoma-derived T-cell suppressor factor/transforming growth factor beta2 inhibits the generation of lymphokine-activated killer (LAK) cells. Int J Cancer 42:562 [DOI] [PubMed] [Google Scholar]
  19. Ledbetter JA, Imboden JB, Schieven GL, Grosmaire LS, Rabinovitch PS, Lindsten T, Thompson CB, June CH (1990) CD28 ligation in T-cell activation: evidence for two signal transduction pathways. Blood 75:1531 [PubMed] [Google Scholar]
  20. Lindsten T, June CH, Ledbetter JA, Stella G, Thompson CB (1989) Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science 244:339 [DOI] [PubMed] [Google Scholar]
  21. Linsley PS, Clark EA, Ledbetter JA (1990) T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci USA 87:5031 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Miescher S, Whiteside TL, Carrel S, Fliedner V von (1986) Functional properties of tumor infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol 136:1899 [PubMed] [Google Scholar]
  23. Nijhuis EWP, Wiel-van Kemenade E, Figdor CG, Lier RAW van (1990) Activation and expansion of tumor-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodies. Cancer Immunol Immunother 32:245 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Ochoa AC, Hasz DE, Rezonzew R, Anderson PM, Bach FH (1989) Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin-2: identification and isolation of effector subsets. Cancer Res 49:963 [PubMed] [Google Scholar]
  25. Ortaldo JR, Mason AT, O'Shea JJ, Smyth MJ, Falk LA, Kennedy ICS, Longo DL, Ruscetti FW (1991) Mechanistic studies of transforming growth factor-beta inhibition of IL-2 dependent activation of CD3-large granular lymphocyte functions. Regulation of IL-2R beta (p75) signal transduction. J Immunol 146:3791 [PubMed] [Google Scholar]
  26. Owen-Schaub LB, De Mars M, Murphy Jr EC, Grimm EA (1991) IL-2 dose regulates TNF-alpha m-RNA transcription and protein secretion in human peripheral blood lymphocytes. Cell Immunol 132:193 [DOI] [PubMed] [Google Scholar]
  27. Pross HF, Baines MG, Rubin P, Shragge P, Patterson MS (1981) Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. The quantitation of natural killer cell activity. J Clin Immunol 1:51 [DOI] [PubMed] [Google Scholar]
  28. Quere P, Thorbecke GJ (1990) Multiple suppressive effects of transforming growth factor-beta1 on the immune response in chickens. Cell Immunol 129:468 [DOI] [PubMed] [Google Scholar]
  29. Ranges GE, Figari IS, Espevik T, Palladino MA (1987) Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med 166:991 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Rook AH, Kehrl JH, Wakefield LM, Roberts AB, Sporn MB, Burlington DB, Lane HC, Fauci AS (1986) Effects of transforming growth factor-beta on the functions of natural killer cells: depressed cytotoxic activity and blunting of interferon responsiveness. J Immunol 136:3916 [PubMed] [Google Scholar]
  31. Rosenberg SA (1988) Immunotherapy of cancer using interleukin-2: current status and future prospects. Immunol Today 9:58 [DOI] [PubMed] [Google Scholar]
  32. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linhan M, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889 [DOI] [PubMed] [Google Scholar]
  33. Rosenblum MG, Cheung L, Murray JL, Bartholomew R (1991) Antibody-mediated delivery of tumor necrosis factor (TNF-alpha): improvement of cytotoxicity and reduction of cellular resistance. Cancer Commun 3:21 [PubMed] [Google Scholar]
  34. Smyth MJ, Strobl SL, Young HA, Ortaldo JR, Ochoa AC (1991) Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor beta1. J Immunol 146:3289 [PubMed] [Google Scholar]
  35. Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA, Shepard HM (1985) Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cell in vitro. Science 230:943 [DOI] [PubMed] [Google Scholar]
  36. Thompson CB, Lindsten T, Ledbetter JA, Kunkel SL, Young HA, Emerson SG, Leiden JM, June CH (1989) CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci USA 86:1333 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Torre-Amione G, Boauchamp RD, Koeppen H, Park BH, Schreiber H, Moses HL, Rowley DA (1990) A highly immunogenic tumor transfected with a murine transforming growth factor type beta1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 87:1486 [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Wrann M, Bodmer MS, Martin R de, Siepl C, Hofer-Warbinek R, Frei K, Hofer E, Fontana A (1987) T cell suppressor factor from human glioblastoma cells in a 12.5-kd protein closely related to transforming growth factor beta. EMBO J 6:1633 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Yang C, Owen-Schaub LB, Roth JA, Grimm EA (1990) Characterisation of OKT3-initiated lymphokine-activated effectors expanded with interleukin-2 and tumor necrosis factor alpha. Cancer Res 50:3526 [PubMed] [Google Scholar]

Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES